Marinus Pharmaceuticals Inc (MRNS) Receives $16.50 Average Price Target from Brokerages

Shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) have been given a consensus rating of “Buy” by the eleven research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $16.50.

MRNS has been the subject of several research reports. Leerink Swann initiated coverage on Marinus Pharmaceuticals in a research note on Wednesday, February 6th. They set an “outperform” rating and a $10.00 price objective for the company. Svb Leerink restated an “outperform” rating on shares of Marinus Pharmaceuticals in a report on Wednesday, February 6th. Zacks Investment Research cut Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 27th. Mizuho cut Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $13.00 to $5.00 in a report on Wednesday, February 27th. Finally, Jefferies Financial Group started coverage on Marinus Pharmaceuticals in a report on Tuesday, March 5th. They set a “buy” rating and a $10.00 target price on the stock.

NASDAQ:MRNS traded down $0.19 during trading hours on Friday, hitting $4.16. 8,477 shares of the stock were exchanged, compared to its average volume of 617,654. Marinus Pharmaceuticals has a 52-week low of $2.36 and a 52-week high of $10.54. The firm has a market cap of $228.64 million, a P/E ratio of -4.70 and a beta of 3.25.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03). Analysts anticipate that Marinus Pharmaceuticals will post -0.86 earnings per share for the current year.

In other Marinus Pharmaceuticals news, CFO Edward F. Smith sold 24,211 shares of Marinus Pharmaceuticals stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $5.03, for a total value of $121,781.33. Following the transaction, the chief financial officer now owns 20,097 shares in the company, valued at approximately $101,087.91. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.10% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in MRNS. Meeder Asset Management Inc. lifted its holdings in shares of Marinus Pharmaceuticals by 1,082.4% during the 4th quarter. Meeder Asset Management Inc. now owns 10,819 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 9,904 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Marinus Pharmaceuticals by 1,465.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,047 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 9,405 shares in the last quarter. Gabelli Funds LLC acquired a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at $49,000. IPG Investment Advisors LLC acquired a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at $50,000. Finally, Citigroup Inc. lifted its holdings in shares of Marinus Pharmaceuticals by 38.4% during the 1st quarter. Citigroup Inc. now owns 13,216 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 3,666 shares in the last quarter. Institutional investors own 66.30% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Story: Why is the price-sales ratio important?

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit